Search results for " Peritoneal"

showing 10 items of 87 documents

Diffuse malignant biphasic peritoneal mesothelioma with cystic areas

2016

We report a case of peritoneal biphasic mesothelioma with cystic areas in a patient with professional exposure to asbestos. It showed focal epithelial glandular and papillary proliferations, also presenting fluid filled cysts, whose wall consisted of a proliferation of spindle cells. Atypia and mitoses were very scanty. EMA, vimentin, CK5/6, D2-40, calretinin and P53 were positive and desmin was negative in both epithelial and spindle areas, including the ones surrounding the cystic spaces. These findings gave an essential aid in the differential diagnosis with a benign cystic mesothelioma and with a cystic epithelial mesothelioma with secondary pseudosarcomatous myofibroblastic proliferati…

MaleMesotheliomaLung NeoplasmsMesothelioma MalignantAscitesAsbestosMesothelioma CysticPemetrexedSettore MED/08 - Anatomia PatologicaAppendicitisCystic Mesothelioma Immunohistochemistry Malignant Mesothelioma Peritoneal Diseases Mesothelial Neoplasms.Diagnosis DifferentialSettore MED/18 - Chirurgia GeneraleCrohn DiseaseOccupational ExposureAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorHumansCisplatinDiagnostic ErrorsPeritoneal NeoplasmsAged
researchProduct

MyD88 is dispensable for resistance toParacoccidioides brasiliensisin a murine model of blood-borne disseminated infection

2008

We have studied the role of MyD88, an adaptor protein of Toll-like receptors (TLRs), in murine defenses against Paracoccidioides brasiliensis in a model of blood-borne disseminated infection. Wild-type (WT) and MyD88-deficient mice infected intravenously with P. brasiliensis yeast cells showed an equivalent fungal burden, as well as similar levels of proinflammatory IL-1beta, IL-6, IL-12p70, tumor necrosis factor (TNF)-alpha and MIP-2, T-helper type 1 (Th1) (IFN-gamma) and Th2 cytokines (IL-4) in tissue homogenates. In vitro production of TNF-alpha, IFN-gamma and IL-12p70, by antigen-stimulated splenocytes from infected animals, was also similar in both types of mice; this production of Th1…

MaleMicrobiology (medical)medicine.medical_treatmentImmunologyNerve Tissue ProteinsMicrobiologyParacoccidioidesMicrobiologyProinflammatory cytokineMicePeritoneal cavitymedicineAnimalsHumansImmunology and AllergyLectins C-TypeMice KnockoutParacoccidioides brasiliensisbiologyMembrane ProteinsParacoccidioidesGeneral MedicineTh1 Cellsbiology.organism_classificationToll-Like Receptor 2Mice Inbred C57BLToll-Like Receptor 4Disease Models AnimalTLR2Infectious Diseasesmedicine.anatomical_structureCytokineMyeloid Differentiation Factor 88Macrophages PeritonealTLR4CytokinesTumor necrosis factor alphaParacoccidioidomycosisFungemiaFEMS Immunology & Medical Microbiology
researchProduct

Toll-like receptor 4 defective mice carrying point or null mutations do not show increased susceptibility toCandida albicansin a model of hematogenou…

2006

We have studied the role of TLR4 in murine defenses against Candida albicans in two TLR4-defective mouse strains: C3H/HeJ mice which have defective TLR4 signaling, and TLR4-/- knockout mice. Both TLR4-defective mice strains experimentally infected with virulent C. albicans cells showed no significant difference in survival as compared with their respective controls. Recruitment of neutrophils to the peritoneal cavity of i.p. infected mice was not affected in TLR4-/-animals, but significantly enhanced in C3H/HeJ mice, compared with their control mice. In vitro production of TNF-alpha by macrophages from both types of TLR4-defective mice, in response to yeasts and hyphae of C. albicans, was n…

MaleNeutrophilsBiologyMicrobiologyInterferon-gammaMicePeritoneal cavityCandida albicansSplenocytemedicineAnimalsPoint MutationGenetic Predisposition to DiseaseCandida albicansMice KnockoutMice Inbred C3HToll-like receptorTumor Necrosis Factor-alphaCandidiasisGeneral MedicineTh1 CellsFlow Cytometrybiology.organism_classificationInterleukin-12Corpus albicansMice Inbred C57BLToll-Like Receptor 4Infectious Diseasesmedicine.anatomical_structureKnockout mouseMacrophages PeritonealTLR4Femalelipids (amino acids peptides and proteins)Tumor necrosis factor alphaMedical Mycology
researchProduct

Modulatory effect of bolinaquinone, a marine sesquiterpenoid, on acute and chronic inflammatory processes

2002

The marine metabolite bolinaquinone is a novel inhibitor of secretory phospholipase A(2) (sPLA(2)), with a potency on the human synovial enzyme (group II) higher than that of manoalide. This activity on the sPLA(2) was confirmed in vivo in the 8-h zymosan rat air pouch on the secretory enzyme accumulation in the pouch exudate. Additionally, bolinaquinone decreased potently the synthesis and release of leukotriene B(4) (LTB(4)) in calcimycin (A23187)-stimulated human neutrophils as a consequence of the inhibition of 5-lipoxygenase activity, as well as PGE(2) and NO production on zymosan-stimulated mouse peritoneal macrophages. This compound exerted anti-inflammatory effects by topical and or…

MaleNeutrophilsGene ExpressionNitric Oxide Synthase Type IIMarine BiologyPharmacologyBone resorptionMicechemistry.chemical_compoundManoalideIn vivoEdemamedicineAnimalsEdemaHumansRats WistarPharmacologybiologyZymosanMembrane ProteinsArthritis ExperimentalPoriferaRatsCarrageenanIsoenzymesRadiographyNitric oxide synthaseDisease Models AnimalchemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologyMacrophages Peritonealbiology.proteinMolecular MedicineTumor necrosis factor alphaNitric Oxide Synthasemedicine.symptomSesquiterpenes
researchProduct

[Spontaneous pneumoperitoneum: a case secondary to thoracic trauma].

2007

Spontaneous pneumoperitoneum is the radiographic manifestation of free air in the peritoneal cavity without visceral perforations and peritoneal signs, and it occurs in about 10% of the cases of pneumoperitoneum. The etiology can be postoperative, thoracic, abdominal, gynecologic, idiopathic; it generally introduces a benign evolution and does not require surgical treatment but just a conservative approach. The authors describe here a case of spontaneous pneumoperitoneum secondary to thoracic trauma. This case is interesting for the occurrence of pneumoperitoneum without clinical peritoneal signs such as fever and leucocytosis, after closed thoracic trauma in absence of pneumothoracic and p…

MaleTime FactorsThoracic InjuriesInfant NewbornOxygen Inhalation TherapyWounds NonpenetratingPNEUMOPERITONEUM - THORACIC INJURY - THORACIC DISEASES - PERITONEAL DISEASESAnti-Bacterial AgentsSettore MED/18 - Chirurgia GeneraleTreatment OutcomePneumoperitoneumHumansAccidental FallsRadiography ThoracicDiureticsAgedFollow-Up StudiesMinerva chirurgica
researchProduct

Refractory congestive heart failure: when the solution is outside the heart

2020

Abstract Refractory congestive heart failure is associated with an ominous prognosis in which the treatments strategies remain scarce and not well validated. In the last years, continuous ambulatory peritoneal dialysis (CAPD) has emerged as a therapeutic alternative in this subset of patients. So far, it has been associated with a significant improvement in functional capacity and quality of life, together with a striking reduction in the risk of readmissions. We present the case of an elderly patient with severe left ventricular dysfunction and severe mitral and tricuspid regurgitation who presents recurrent admissions for anasarca. After its inclusion in a CAPD programme, the patient expe…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtymedicine.medical_treatmentPeritoneal dialysisCase ReportRegurgitation (circulation)030204 cardiovascular system & hematologyAnasarcaVentricular Function LeftPeritoneal dialysis03 medical and health sciences0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryQuality of lifeRefractoryInternal medicinemedicineHumans030212 general & internal medicineAgedHeart Failurebusiness.industryContinuous ambulatory peritoneal dialysismedicine.diseaseTricuspid Valve InsufficiencyTreatmentRefractory congestive heart failureEchocardiographylcsh:RC666-701Heart failureQuality of LifeCardiologymedicine.symptomDiureticCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

Continuous ambulatory peritoneal dialysis and clinical outcomes in patients with refractory congestive heart failure.

2012

A B S T R A C T Introduction and objectives: Peritoneal dialysis has been proposed as a therapeutic alternative for patients with refractory congestive heart failure. The objective of this study was to assess its effect on long-term clinical outcomes in patients with advanced heart failure and renal dysfunction. Methods: A total of 62 patients with advanced heart failure (class III/IV), renal dysfunction (glomerular filtration<60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment and at least 2 previous hospitalizations for heart failure were invited to participate in a continuous ambulatory peritoneal dialysis program. Of these, 34 patients were excluded and adj…

Malemedicine.medical_specialtymedicine.drug_classEndpoint Determinationmedicine.medical_treatmentDrug ResistanceUltrafiltrationPeritoneal dialysisCohort StudiesPeritoneal Dialysis Continuous AmbulatoryRisk FactorsInternal medicineClinical endpointmedicineRisk of mortalityHumansProspective StudiesPropensity ScoreAgedHeart Failurebusiness.industryContinuous ambulatory peritoneal dialysisHazard ratioGeneral MedicineLoop diureticmedicine.diseaseSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeHeart failureCardiologyFemalebusinessFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure.

2012

Aims Continuous ambulatory peritoneal dialysis (CAPD) has been proposed as an additional therapeutic resource for patients with advanced congestive heart failure (CHF). The objective of this study was to determine the therapeutic role of CAPD, in terms of surrogate endpoints, in the management of patients with advanced CHF and renal dysfunction. A total of 57 candidates with New York Heart Association (NYHA) class III/IV CHF, renal dysfunction (glomerular filtration rate , 60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment, and at least two previous hospitalizations for acute heart failure (AHF) were invited to be included in the CAPD programme; however, 25 pa…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentRenal functionurologic and male genital diseasesKidneySeverity of Illness IndexPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryInternal medicineSurveys and QuestionnairesmedicineAmbulatory CareHumanscardiovascular diseasesProspective StudiesRenal InsufficiencyProspective cohort studyHeart Failurebusiness.industrySurrogate endpointContinuous ambulatory peritoneal dialysisLoop diureticBrain natriuretic peptidemedicine.diseaseHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersGlomerular Filtration RateEuropean journal of heart failure
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Toll-like receptor 2 mediates prostaglandin E2 production in murine peritoneal macrophages and splenocytes in response to Candida albicans

2004

The involvement of Toll-like receptor 2 (TLR2) and TLR4 in triggering signal transduction pathways leading to prostaglandin E(2) (PGE(2)) production in response to Candida albicans has been studied in cells from wild-type, TLR2-/- and TLR4-/- knockout mice. In vitro PGE(2) production by macrophages challenged with zymosan, yeast or hypha cells was strongly inhibited in TLR2-deficient cells, but not in TLR4-/- cells, as compared to macrophages from wild-type mice. PGE(2) production was dependent on de novo cyclooxygenase-2 (Cox2) synthesis, since unchallenged cells failed to produce PGE(2) and specific Cox2 inhibition during challenge totally blocked PGE(2) production. Similar results were o…

Malemedicine.medical_treatmentReceptors Cell SurfaceBiologyMicrobiologyDinoprostoneMicechemistry.chemical_compoundCandida albicansmedicineAnimalsProstaglandin E2Candida albicansMolecular BiologyCells CulturedMice KnockoutToll-like receptorZymosanGeneral Medicinebiology.organism_classificationMolecular biologyToll-Like Receptor 2Corpus albicansToll-Like Receptor 4TLR2chemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologyMacrophages PeritonealTLR4Femalelipids (amino acids peptides and proteins)Signal Transductionmedicine.drugProstaglandin EResearch in Microbiology
researchProduct